| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Picfeltarraenin IA targets multiple proteins and pathways. It is an inhibitor of acetylcholinesterase (AChE), the enzyme responsible for the hydrolysis of the neurotransmitter acetylcholine. Inhibition of AChE leads to increased acetylcholine levels in the synaptic cleft, enhancing cholinergic transmission. The compound is also a potential inhibitor of PI3K (phosphoinositide 3-kinase) and EGFR (epidermal growth factor receptor), both of which are key signaling molecules involved in cell proliferation, survival, and cancer. Additionally, Picfeltarraenin IA inhibits both the classical and alternative pathways of the complement system, suggesting anti-inflammatory and immunomodulatory activities. Its multiple targets make it a compound of interest for the treatment of herpes infections, cancer, and inflammatory conditions.
|
|---|---|
| ln Vitro |
In vitro, Picfeltarraenin IA has been shown to inhibit acetylcholinesterase activity, making it a potential candidate for the treatment of conditions associated with cholinergic dysfunction. Its inhibition of PI3K and EGFR suggests potential anticancer activity. The compound's ability to inhibit both classical and alternative complement pathways indicates anti-inflammatory potential. However, specific in vitro activity data, such as IC₅₀ values for AChE, PI3K, EGFR, and complement pathway inhibition, are not extensively documented in the public literature. The compound is typically evaluated in enzyme activity assays and cell-based models to characterize its inhibitory effects.
|
| ln Vivo |
In vivo, Picfeltarraenin IA has been studied for its therapeutic potential in infection, cancer, and inflammation. Its inhibition of AChE suggests potential applications in neurodegenerative diseases or conditions involving cholinergic dysfunction. The compound's anti-complement activity may contribute to its anti-inflammatory effects in vivo. However, detailed in vivo efficacy data for Picfeltarraenin IA are limited in the public literature. Further studies are needed to confirm its therapeutic potential in animal models of infection, cancer, and inflammatory diseases.
|
| Enzyme Assay |
For in vitro enzyme assays, Picfeltarraenin IA is evaluated for its ability to inhibit acetylcholinesterase (AChE) activity. The enzyme is incubated with the substrate acetylthiocholine iodide in the presence of varying concentrations of the compound. The hydrolysis of acetylthiocholine produces thiocholine, which reacts with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to produce a yellow color measured at 412 nm. Inhibition is calculated by comparing the rate of hydrolysis in the presence and absence of the compound. For PI3K and EGFR inhibition assays, the compound is incubated with the respective kinase enzymes and substrates, and phosphorylation is measured using radioactive or fluorescence-based detection methods. For complement pathway inhibition, the compound is incubated with complement components, and hemolytic activity is measured.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines (e.g., breast cancer, lung cancer) are cultured in appropriate media and treated with Picfeltarraenin IA at various concentrations. Cell viability is measured by MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining and caspase activity assays. Cell signaling pathways, including PI3K/AKT and EGFR/MAPK, are analyzed by Western blotting. For anti-inflammatory studies, immune cells are stimulated with inflammatory stimuli in the presence of the compound, and cytokine production is measured by ELISA. For AChE inhibition studies, neuronal cell lines or primary neurons are treated with the compound, and acetylcholine levels or cholinergic signaling is assessed.
|
| Animal Protocol |
For in vivo animal studies, Picfeltarraenin IA is typically administered orally or intraperitoneally. In models of cancer, tumor-bearing mice are treated with the compound, and tumor growth is monitored. In models of inflammation, the compound is administered to animals with induced inflammatory conditions, and inflammatory markers, tissue damage, and clinical signs are assessed. In models of neurodegenerative diseases, the compound's effects on cognitive function and cholinergic signaling are evaluated. Pharmacokinetic and toxicological studies may also be performed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Picfeltarraenin IA are not extensively characterized in the literature. As a triterpenoid glycoside with a molecular weight of 762.92, the compound is expected to have poor oral bioavailability due to its high molecular weight and hydrophilic sugar moieties. It is likely administered parenterally in research settings. The compound's metabolism, distribution, and excretion have not been studied in detail. Further pharmacokinetic studies are needed to determine its absorption, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Picfeltarraenin IA are limited. As a natural triterpenoid, the compound may have a favorable safety profile based on the traditional use of Picria fel-terrae. However, comprehensive toxicological studies have not been published. Standard laboratory safety precautions should be observed when handling the compound. The compound is not intended for human use in research settings.
|
| References | |
| Additional Infomation |
According to reports, Picria felterrae contains picfeltarracemin IA, and there is relevant data.
Picfeltarraenin IA is a research compound with no clinical trial or regulatory approval status. It is a triterpenoid isolated from Picria fel-terrae Lour, a plant used in traditional medicine. The compound is of interest for its multiple biological activities, including AChE inhibition, PI3K/EGFR inhibition, and complement pathway inhibition. It has potential applications in the treatment of herpes infections, cancer, and inflammation. The compound is used primarily as a reference standard and in pharmacological studies of these activities. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C41H62O13
|
|---|---|
| Molecular Weight |
762.9232
|
| Exact Mass |
762.419
|
| CAS # |
97230-47-2
|
| PubChem CID |
21635746
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
861.5±65.0 °C at 760 mmHg
|
| Flash Point |
255.3±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
5.05
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
54
|
| Complexity |
1570
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](CO[C@H]2O[C@@H]3CC[C@@H]4C(=CC[C@@H]5[C@]4(C(=O)C[C@]6([C@]5(C[C@H]([C@@H]6[C@]7(C(=O)C=C(O7)C(C)C)C)O)C)C)C)C3(C)C)O)O)O)O)O
|
| InChi Key |
WPXIIGGPWPYUSJ-ZRJNTGDHSA-N
|
| InChi Code |
InChI=1S/C41H62O13/c1-18(2)24-14-26(44)41(9,54-24)34-22(42)15-38(6)25-12-10-20-21(40(25,8)27(45)16-39(34,38)7)11-13-28(37(20,4)5)52-36-33(30(47)23(43)17-50-36)53-35-32(49)31(48)29(46)19(3)51-35/h10,14,18-19,21-23,25,28-36,42-43,46-49H,11-13,15-17H2,1-9H3/t19-,21+,22+,23+,25-,28+,29-,30-,31+,32+,33+,34-,35-,36-,38-,39+,40-,41+/m0/s1
|
| Chemical Name |
(2S)-2-[(3R,8S,9R,10R,13R,14S,16R,17R)-3-[(2S,3R,4S,5R)-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-16-hydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-5-propan-2-ylfuran-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~131.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3108 mL | 6.5538 mL | 13.1075 mL | |
| 5 mM | 0.2622 mL | 1.3108 mL | 2.6215 mL | |
| 10 mM | 0.1311 mL | 0.6554 mL | 1.3108 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
